Breakthrough trial tests immune drug combo against aggressive stomach cancers
NCT ID NCT05008783
Summary
This large Phase 3 trial tested whether adding a new immune-boosting drug called AK104 to standard chemotherapy works better than chemotherapy alone for people with advanced stomach or gastroesophageal cancer. The study involved 610 adults who had not received prior treatment for their advanced cancer. Researchers compared how long patients lived and how well the cancer responded between the two treatment groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, 200032, China
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, 100143, China
-
The First Affiliated Hospital of Zhejiang University Medical College
Hangzhou, Zhejiang, 310003, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610044, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650118, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 20032, China
Conditions
Explore the condition pages connected to this study.